interferon alfa-2a, recombinant, a parenteral antineoplastic drug. ▪ INDICATIONS: It is administered in the treatment of AIDS-related Kaposi’s sarcoma, hairy cell and chronic myelogenous leukemia, and chronic hepatitis C. It also has a variety of unlabeled or investigational uses. ▪ CONTRAINDICATIONS: Caution is recommended in prescribing this product for patients with severe cardiovascular disease. ▪ ADVERSE EFFECTS: Among reported adverse effects are influenza-like symptoms, particularly at the beginning of therapy with the drug; confusion; dizziness; nervousness; depression; anorexia; nausea; vomiting; diarrhea; throat inflammation; dry and itching skin; alopecia; diaphoresis; blood pressure changes; and tachycardia.
